retatrutide triple hormone receptor agonist obesity meets primary endpoints in two phase III trials, reporting up to 22.6% weight loss – touchENDOCRINOLOGY retatrutide phase 2 trial results
Pay in 4 interest-free payments of $5.30 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
























